Greenwich LifeSciences Inc Ordinary Shares GLSI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $13.66
- Day Range
- $13.30–14.09
- 52-Week Range
- $7.58–21.44
- Bid/Ask
- $13.60 / $13.97
- Market Cap
- $180.61 Mil
- Volume/Avg
- 23,338 / 33,909
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual’s immune system to selectively attack cancer cells to inhibit the spread of cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
Comparables
Valuation
|
Metric
|
GLSI
|
NUVL
|
MGNX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 30.56 | 10.66 | 3.89 |
Price/Sales | — | — | 5.66 |
Price/Cash Flow | — | — | — |
Price/Earnings
GLSI
NUVL
MGNX
Financial Strength
|
Metric
|
GLSI
|
NUVL
|
MGNX
|
|---|---|---|---|
Quick Ratio | 5.34 | 17.23 | 2.53 |
Current Ratio | 5.34 | 17.44 | 2.71 |
Interest Coverage | — | — | −128.87 |
Quick Ratio
GLSI
NUVL
MGNX
Profitability
|
Metric
|
GLSI
|
NUVL
|
MGNX
|
|---|---|---|---|
Return on Assets (Normalized) | −98.41% | −23.36% | −59.21% |
Return on Equity (Normalized) | −105.38% | −24.62% | −120.96% |
Return on Invested Capital (Normalized) | −109.67% | −28.80% | −102.88% |
Return on Assets
GLSI
NUVL
MGNX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Mkfztzdb | Fnbjr | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Cmypmmlfq | Qckhtf | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nvdyqvp | Cwdwpb | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zrtskpkx | Pnsksn | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Mhwzmhn | Dblsw | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Thyjzyh | Ygzfc | $29.2 Bil | |||
| Moderna Inc
MRNA
| Kpxdqjsp | Fxwcl | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Rxkynpg | Pzrv | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Btdqqzsw | Zgndlx | $13.2 Bil | |||
| Incyte Corp
INCY
| Lybczgl | Pdvjzmr | $13.0 Bil |
United States